Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

237.60 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
US Stock Market Movers: Top Gainers and Losers for the Session ↗
Via Chartmill
News headline image
Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction ↗
Glaukos’ two newer launches are carrying the company, and its 2027 target may be too low. Here’s what to watch. 
Via The Motley Fool
Top US Stock Gainers and Losers for Oct. 29, 2026 ↗
Via Chartmill
Gap-Up and Gap-Down Stocks in the Oct. 29, 2026 Session ↗
Via Chartmill
Glaukos (NYSE:GKOS): High Growth Momentum Meets a Breakout Setup ↗
Via Chartmill
Glaukos (NYSE:GKOS) Passes Minervini Trend Template and High-Growth Momentum Screen ↗
Via Chartmill
GKOS (Glaukos Corp) Shows Strong Trend Template Compliance and High Growth Momentum on ChartMill ↗
Via Chartmill
Premarket Gainers and Losers on Oct. 29, 2026 ↗
Via Chartmill
News headline image
Glaukos (GKOS) Q3 2026 Earnings Call Transcript ↗
Record sales and margin expansion driven by iDose TR and Epioxa launches. 
Via The Motley Fool
Topics Earnings
News headline image
Glaukos Q3 Earnings Call Highlights ↗
Glaukos (NYSE:GKOS) reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma... 
Via MarketBeat
Topics Earnings
After-Hours Movers: LABT, NCPL Top Gainers; Fortinet, AUROW Top Losers ↗
Via Chartmill
News headline image
Glaukos Announces Third Quarter 2026 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
From Glaukos Corporation
Via Business Wire
News headline image
If You Invested $1000 In Glaukos Stock 10 Years Ago, You Would Have This Much Today ↗
Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 3.9% on an annualized basis producing an average annual return of 17.45%. Currently, Glaukos has a market capitalization of... 
Via Benzinga
News headline image
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today ↗
Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized basis producing an average annual return of 26.17%. Currently, Glaukos has a market capitalization of... 
Via Benzinga
News headline image
Glaukos Announces Participation in Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos (GKOS) Q2 2026 Earnings Call Transcript ↗
iDose TR drove $74M in Q2 revenue as Glaukos raised full-year guidance. 
Via The Motley Fool
Topics Earnings
News headline image
Glaukos Q2 Earnings Call Highlights ↗
Glaukos (NYSE:GKOS) reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth... 
Via MarketBeat
Topics Earnings
News headline image
Glaukos Announces Second Quarter 2026 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now? ↗
Disposition represented 19% of insider's equity holdings under pre-established Rule 10b5-1 trading plan. Thurman retains 43,681 shares worth approximately $6.77 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions. 
Via The Motley Fool
News headline image
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos (GKOS) Q1 2026 Earnings Transcript ↗
Glaukos (GKOS) Q1 2026 Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.